Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
1.
Zentralbl Gynakol ; 123(7): 383-9, 2001 Jul.
Article in German | MEDLINE | ID: mdl-11534298

ABSTRACT

The paper reports on four patients with choriocarcinoma. In two of them, the choriocarcinoma was found after abortion, in one of them following termination of pregnancy, and in the last patient a hydatidiform mole was present. In all patients increased beta-HCG was found. One patient had lung metastasis at the time of diagnosis. In another patient, choriocarcinoma was suspected owing to ultrasonographic vaginal examination. According to the Bagshawe Score, 3 patients were low-risk and were subjected to methotrexate. One patient was medium-risk and received PEB chemotherapy. All four patients are regarded as cured.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Choriocarcinoma/diagnosis , Choriocarcinoma/drug therapy , Methotrexate/therapeutic use , Uterine Neoplasms/diagnosis , Uterine Neoplasms/drug therapy , Abortion, Induced , Adult , Antineoplastic Combined Chemotherapy Protocols/administration & dosage , Bleomycin/administration & dosage , Choriocarcinoma/pathology , Chorionic Gonadotropin, beta Subunit, Human/blood , Cisplatin/administration & dosage , Etoposide/administration & dosage , Female , Humans , Lung Neoplasms/diagnostic imaging , Lung Neoplasms/secondary , Neoplasm Metastasis , Pregnancy , Radiography , Uterine Neoplasms/pathology
3.
Ann Oncol ; 5 Suppl 2: 123-5, 1994.
Article in English | MEDLINE | ID: mdl-7515644

ABSTRACT

In high-grade malignant non-Hodgkin's lymphomas (hNHL) recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) was evaluated as support to chemotherapy. In a phase III trial, 172 patients (age 18-73 years, stage II-IV) were risk-stratified according to LDH levels and lymphoma size and randomized to receive rhGM-CSF (400 micrograms) (87 patients) or placebo (85 patients) subcutaneously days 8-14 of each cycle of an intensified COP-BLAM regimen. RhGM-CSF significantly reduced the length and nadir of neutropenia, the length of fever episodes, the frequency of all and of severe infections, and of hospitalization and antibiotic requirements. Complete response rates were 63% for all patients and 64% vs. 61% (n.s.) in the rhGM-CSF vs. the control group. Deviations from protocol in applied dosages of myelotoxic drugs and in cycle intervals maintained differed slightly in favor of the rhGM-CSF arm. However, there were no significant differences in overall survival between the GM-CSF treatment and control groups (21 vs. 23 months). Early relapse rates were markedly lower than in the standard-dose COP-BLAM/IMVP-16 regimen. Thus, GM-CSF abates toxic side effects of chemotherapy and may help to maintain dose intensity in high-risk hNHL.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Granulocyte-Macrophage Colony-Stimulating Factor/therapeutic use , Immunologic Factors/therapeutic use , Lymphoma, Non-Hodgkin/drug therapy , Neutropenia/therapy , Adolescent , Adult , Aged , Antineoplastic Combined Chemotherapy Protocols/adverse effects , Bleomycin/administration & dosage , Combined Modality Therapy , Cyclophosphamide/administration & dosage , Doxorubicin/administration & dosage , Female , Fever/etiology , Humans , Infections/etiology , Length of Stay , Lymphoma, Non-Hodgkin/mortality , Lymphoma, Non-Hodgkin/radiotherapy , Male , Middle Aged , Neutropenia/chemically induced , Prednisone/administration & dosage , Procarbazine/administration & dosage , Prospective Studies , Recombinant Proteins/therapeutic use , Remission Induction , Risk , Survival Analysis , Treatment Outcome , Vincristine/administration & dosage
4.
Radiologe ; 33(5): 308-12, 1993 May.
Article in German | MEDLINE | ID: mdl-8516440

ABSTRACT

Forty-two patients with locally advanced breast cancer (n = 8) or recurrent breast cancer (n = 34) received regional chemotherapy (mitoxantrone 25 mg/m2 per 24 h) via the internal mammary artery or other vessels of the subclavian artery. To prevent artery thrombosis 500-1000 U heparin per hour were administered i.v. Tumour perfusion was monitored by intra-arterial angio-CT. Remission rates (CR + PR) were 100% (primary breast cancer) and 89% (recurrent tumours), respectively. Intra-arterial chemotherapy was well tolerated. No complications were noted.


Subject(s)
Breast Neoplasms/drug therapy , Mitoxantrone/administration & dosage , Neoplasm Recurrence, Local/drug therapy , Adult , Aged , Angiography , Breast Neoplasms/diagnostic imaging , Female , Humans , Infusions, Intra-Arterial , Mammary Arteries , Middle Aged , Mitoxantrone/adverse effects , Monitoring, Physiologic/methods , Neoplasm Recurrence, Local/diagnostic imaging , Tomography, X-Ray Computed
SELECTION OF CITATIONS
SEARCH DETAIL
...